• Making TNBC Target Validation More Measurable

  2026-09-24

  A recent preclinical study positions the Lin28B–Let-7–PBK axis as a potential therapeutic vulnerability in triple-negative breast cancer. This article examines how sensitive immunoblotting can strengthen target-validation workflows, where evidence is promising but still preliminary, and how to interpret protein readouts alongside RNA and functional assays.

• Sodium Ascorbate: Cancer Assay Workflows

  2026-09-24

  Build a solvent-aware workflow for testing Sodium Ascorbate in ROS-linked cancer-cell assays, from controlled dosing to orthogonal cell-death readouts. The guide also separates established glioblastoma findings from a new ESCC immunotherapy biomarker study, helping researchers avoid unsupported cross-domain conclusions.

• GTP Solution for p21 mRNA Workflows

  2026-09-23

  Learn how a high-purity GTP stock can support in vitro transcription and quality-controlled p21 mRNA–LNP research. The workflow connects nucleotide handling to localized bladder cancer assays while clearly separating reagent use from therapeutic evidence.

• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-09-23

  This preprint examines how Shufeng Xingbi Therapy affects allergic rhinitis in rats through nasal inflammation, Th1/Th2-related signaling, and intestinal microbial changes. Its main contribution is a multi-layer analysis linking improved symptoms and mucosal pathology with altered bacterial composition, higher short-chain fatty acids, and reduced IgE, IL-4, STAT5, STAT6, and GATA3 signals.

• Bafilomycin C1: From Lysosomes to Safer Screens

  2026-09-22

  A translational guide to using Bafilomycin C1 as a mechanistically interpretable V-ATPase perturbation in autophagy assays, high-content phenotypic screens, and iPSC-derived models.

• Anti-ROR1 Antibody Workflow Guide

  2026-09-22

  Build a connected workflow from recombinant ROR1 binding and cell-surface profiling to Wnt5a pathway perturbation. This guide also explains how to use the reference liver-injury study to strengthen orthogonal assay design without overstating cross-disease evidence.

• Palonosetron for Chemotherapy-Induced Nausea and Vomiting

  2026-09-21

  Ruhlmann and Herrstedt review why palonosetron may provide clinically useful advantages over earlier 5-HT3 receptor antagonists, linking prolonged receptor engagement with protection against acute and delayed chemotherapy-induced nausea and vomiting. The paper’s practical contribution is a critical comparison of pharmacology, preclinical emesis models, comparative trials, tolerability, and the limits of translating receptor-level differences into better patient outcomes.

• Polymyxin B: From Membrane Damage to Translation

  2026-09-21

  Polymyxin B sulfate is more than a membrane-active antibiotic: it is a translational research tool for connecting bacterial killing, immune signaling, and infection-model design. This article shows how to use it in Gram-negative bacterial infection research while interpreting dendritic cell, sepsis, bacteremia, and microbiome-immunotherapy findings without overstating clinical relevance.

• ERADECs: Hijacking ERAD to Degrade Membrane Proteins

  2026-09-20

  Song and colleagues introduce ERAD-engaging chimeras (ERADECs), a small-molecule strategy that redirects endoplasmic reticulum-associated degradation toward transmembrane proteins. Desonide-based ERADECs produced SYVN1- and ERAD-dependent PD-L1 degradation, strong in vivo activity, and an initial extension to mutant HTT, while also defining important limits for translation.

• Vincristine Sulfate: A Mechanism-First Assay Guide

  2026-09-19

  Vincristine sulfate is a mechanistically defined microtubule disrupter for cancer research. This guide connects target engagement, microtubule dynamics, assay design, and evidence interpretation while distinguishing product data from broader translational conclusions.

• Vincristine Sulfate: Evidence-to-Assay Guide

  2026-09-18

  Vincristine sulfate is a powerful tool for cancer research, but its value depends on linking tubulin biology to carefully chosen assay endpoints. This guide develops an evidence-to-assay framework, distinguishes direct product evidence from cross-domain insights, and outlines practical controls for studying microtubule dynamics.

• EMD638683: SGK1 Inhibitor Workflow Guide

  2026-09-18

  EMD638683 enables mechanism-focused studies of SGK signaling in endothelial stiffness, sodium-channel regulation, proliferation, and stress-induced cell death. This practical guide connects literature-based vascular assays with reproducible dosing, controls, readouts, and troubleshooting for cardiovascular and oncology research.

• EZ Cap™ OVA mRNA for Immune Research

  2026-09-17

  EZ Cap™ OVA mRNA is a 1416-nucleotide, Cap 1-capped Ovalbumin mRNA preparation for immune response immunogen studies, gene expression studies, and vaccine development research. Its vendor-reported formulation combines approximately 1 mg/mL mRNA, a poly(A) tail, and 90–99% capping efficiency in a citrate buffer.

• IL-2, Human Recombinant in Ferroptosis Assays

  2026-09-17

  Explore how IL-2, human recombinant can strengthen mechanistic studies linking carbon-ion radiotherapy, ferroptosis, and immune-cell function. This guide translates recent gastric cancer findings into a controlled assay strategy while clearly separating established evidence from experimental hypotheses.

• Tacrine Hydrochloride Hydrate: From Target to Translation

  2026-09-16

  Tacrine hydrochloride hydrate, also known as Tetrahydroaminacrine, is more than a historical acetylcholinesterase inhibitor. This thought-leadership perspective shows how its dual-site cholinesterase pharmacology, neuroprotective hypotheses, and well-defined translational liabilities can guide rigorous Alzheimer’s disease research, assay design, and next-generation multi-target discovery.

8558 records 1/571 page Next 12345 下5页 Last page